Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)
Completed
Conditions studied: Attention Deficit Hyperactivity Disorder (ADHD)
In brief
The purpose of this study is develop a new assessment tool for Attention Deficit-Hyperactivity Disorder (ADHD) and to then test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls).
Key facts
- Study ID
- NCT02407496
- Run by
- Think Now Incorporated
- People needed
- 80
- Starts
- 2014-06-01
- Expected to finish
- 2015-09-01
- Last updated by the study team
- 2020-12-10
Who can join
Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Specific inclusion criteria for ADHD are:
- meet established DSM-5 criteria for ADHD predominately inattentive or combined subtype with clinically significant levels of impairment, diagnosed by structured clinical interview, the Mini International Neuropsychiatric Interview, and corroborating information
- Clinical Global Impression-Severity (CGI-S) score ≥ 4 for ADHD
- no lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse, or substance dependence (except nicotine) as assessed wit the MINI
- able in the opinion of the investigator to complete all required study procedures.
You may not qualify if…
- Exclusion criteria for both groups are:
- History of diagnosis of childhood disorder other than ADHD (e.g. autism, dyslexia)
- history of any general medical condition likely to require chronic use of medication with identified CNS effects suspected to alter cognitive performance
- history of seizure disorder, brain tumor, other major neurological disorder or head injury resulting in loss of consciousness
- serious oxygen deprivation
- current psychopathology requiring ongoing treatment with antipsychotic medications, mood stabilizers, benzodiazepines, or anticonvulsants
- current untreated psychopathology which is rated to be primary in terms of severity (greater than ADHD severity)
- current treatment with guanfacine.
Where it is running
- UCLA Semel Institute — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.